182 related articles for article (PubMed ID: 18991793)
1. Rimonabant for the treatment of obesity.
Samat A; Tomlinson B; Taheri S; Thomas GN
Recent Pat Cardiovasc Drug Discov; 2008 Nov; 3(3):187-93. PubMed ID: 18991793
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
Patel PN; Pathak R
Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
[TBL] [Abstract][Full Text] [Related]
4. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
5. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ; Bousser MG; Fox KA; Creager MA; Despres JP; Easton JD; Hamm CW; Montalescot G; Steg PG; Pearson TA; Cohen E; Gaudin C; Job B; Murphy JH; Bhatt DL;
Lancet; 2010 Aug; 376(9740):517-23. PubMed ID: 20709233
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Cahill K; Ussher M
Cochrane Database Syst Rev; 2007 Jul; (3):CD005353. PubMed ID: 17636794
[TBL] [Abstract][Full Text] [Related]
7. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Pacher P
Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
[No Abstract] [Full Text] [Related]
9. [New drugs; rimonabant].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
12. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Tucci SA; Halford JC; Harrold JA; Kirkham TC
Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
Woods SC
JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
[TBL] [Abstract][Full Text] [Related]
15. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
16. Reducing cardiometabolic risk through selective antagonism of CB1 receptors.
Van Gaal L
Clin Cornerstone; 2007; 8 Suppl 6():S24-9. PubMed ID: 17948364
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
18. CB(1) receptor antagonism: biological basis for metabolic effects.
Di Marzo V
Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
[TBL] [Abstract][Full Text] [Related]
19. Effect of rimonabant on weight reduction and cardiovascular risk.
van Oosten B; Killestein J; Polman Ch
Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
[No Abstract] [Full Text] [Related]
20. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
